Protocol Ledger

NCT05399459 · Phase III · COMPLETED

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Interventional Phase III clinical trial protocol NCT05399459 sponsored by Pfizer in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-09 Enrollment: 897 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05399459
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)897 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05399459
Protocol FieldVerified Registry Value
NCT IdentifierNCT05399459
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment897 participants (ACTUAL)
Registered Start Date2022-08-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05399459
Hospital Research SiteLocationSite Profile
University Hospital,Kyoto Prefectural University of MedicineKyoto, JapanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI